Cargando…
NK Cell-Based Glioblastoma Immunotherapy
Glioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its clinical outcome, imposing the need for innovative therapeutic approaches. The main reason for the poo...
Autores principales: | Golán, Irene, Rodríguez de la Fuente, Laura, Costoya, Jose A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315402/ https://www.ncbi.nlm.nih.gov/pubmed/30567306 http://dx.doi.org/10.3390/cancers10120522 |
Ejemplares similares
-
Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy
por: Arnesen, Victoria Smith, et al.
Publicado: (2021) -
RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells
por: Orozco-Morales, Mario, et al.
Publicado: (2015) -
NK Cell-Based Immunotherapy in Colorectal Cancer
por: Della Chiesa, Mariella, et al.
Publicado: (2022) -
NK Cell-Based Immunotherapy in Cancer Metastasis
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2018) -
The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)